John Crowley, CEO of the Biotechnology Innovation Organization (BIO), led a delegation of board members to Japan last week for strategic discussions on pharmaceutical development and regulatory frameworks.
On March 19, the team met with JBA President Osamu Nagayama and Steering Committee Chairman Dr. Hitoshi Kuboniwa, along with other JBA members, at a productive roundtable in Tokyo.
During their visit, the delegation engaged with key stakeholders across Japan's healthcare ecosystem, including representatives from the Cabinet Office, various ministries, pharmaceutical companies, embassy officials, and the Pharmaceuticals and Medical Devices Agency (PMDA). Their primary focus was gathering insights on drug lag issues affecting medicine availability in the Japanese market.
The visit represents an important step in strengthening the US-Japan biotech partnership as both countries work together to accelerate patient access to innovative treatments.
